Revenue: As of FY2025, the actual value is USD 7.009 M.

EPS: As of FY2025, the actual value is USD -11.16.

EBIT: As of FY2025, the actual value is USD -269.32 M.

Consolidated Financial Metrics

Consolidated Net Loss

Sharps Technology, Inc. reported a consolidated net loss of - $282,502,126 in 2025, a significant increase from - $9,296,201 in 2024. This net loss in 2025 was primarily due to stock compensation charges, unrealized losses on Solana holdings, and asset impairments.

Consolidated Cash Flow from Operating Activities

Cash used in operating activities increased to - $10,990,651 in 2025, compared to - $4,401,392 in 2024. The increase in cash used in operations in 2025 was mainly attributable to digital asset transaction fees and higher general and administrative expenses, partially offset by reduced research and development activities.

Consolidated Working Capital

Working capital as of December 31, 2025, was $14,187,484, a substantial improvement from a working capital deficiency of - $2,011,679 as of December 31, 2024. The increase in working capital in 2025 was directly impacted by cash provided from the August 2025 Private Investment in Public Equity Offering (PIPE).

Digital Assets Holdings

As of December 31, 2025, the fair market value of digital assets was $250,111,125. The company held 2,077,799 total SOL units, consisting of 1,427,857 liquid SOL units and 649,942 locked SOL units. The cost basis of SOL as of December 31, 2025, was $403,063,288, resulting in an unrealized loss on digital assets of - $152,952,163 in 2025. This loss resulted from a decrease in the average cost basis of SOL (approximately $198) to its market value ($124) as of December 31, 2025. Approximately 95% of the SOL units were staked as of December 31, 2025.

Segmented Financial Performance

Medical Device Packaging Segment (Continuing Operations)

Net revenue for this segment was $204,120 in 2025, compared to $0 in 2024. The segment reported a gross margin loss of - $413,325 in 2025, also from $0 in 2024. Research and development expenses decreased to $198,762 in 2025 from $531,233 in 2024, as the company curtailed its medical device activities and does not intend to engage in R&D and manufacturing for medical devices going forward. Selling, general and administrative expenses were $132,539 in 2025, down from $472,604 in 2024. The loss from operations for this segment was - $744,626 in 2025, an improvement from - $1,003,838 in 2024.

Digital Asset Treasury Segment

This segment generated net staking revenue of $6,805,009 in 2025, with no revenue in 2024. It also recognized $101,331,513 from warrant issuance to a related party and incurred $3,433,333 in consulting fees to related parties in 2025, both with no corresponding figures in 2024. Selling, general and administrative expenses were $1,079,853 in 2025. The segment experienced a realized loss on digital assets of - $1,286,284, digital asset transaction expenses of $872,934, and a realized loss on derivatives of - $4,986,500 in 2025, with no activity in 2024 for these categories. The loss from operations for this segment was - $254,151,072 in 2025.

Corporate (Non-Segment)

Selling, general and administrative expenses for corporate activities increased to $14,839,676 in 2025 from $4,563,763 in 2024. Net interest expense decreased to - $416,660 in 2025 from - $1,664,712 in 2024, due to higher average cash balances in 2025 from offerings and debt repayment. A fair market value adjustment on warrants resulted in a gain of $4,803,098 in 2025, compared to a gain of $3,016,936 in 2024. Other expense in 2024 was - $1,009,891, primarily due to the forfeiture of a $1 million escrow deposit. The loss from operations for corporate activities was - $14,839,676 in 2025, compared to - $4,563,763 in 2024.

Discontinued Operations (Safegard Medical Kft)

Net loss from discontinued operations was - $12,166,690 in 2025, up from - $4,070,935 in 2024. A loss on disposal of - $1,078,348 was recorded in 2025. Fixed asset impairment included in discontinued operations was $7,497,669 in 2025, compared to $1,770,000 in 2024.

Unique Metrics

Sharps Technology, Inc. held over 2.0 million SOL units as of December 31, 2025. The company recognized $6,805,009 in net staking revenue in 2025, with approximately 95% of its SOL holdings staked. A 20-year consulting agreement with Sol Edge Limited includes an upfront annual fee of $10 million for the first year. The Board approved a share repurchase program of up to $100,000,000 of common stock in October 2025, with 867,678 shares repurchased for $1,571,507 through March 2026. A margin loan of $3,084,931, outstanding as of December 31, 2025, was repaid on February 17, 2026, releasing 40,000 SOL as collateral.

Outlook/Guidance

Sharps Technology, Inc. intends to expand its distribution platform by representing established third-party manufacturers of complementary medical products. The company plans to prioritize long-term growth, potentially utilizing proceeds from SOL sales to fund expansion plans and develop its own digital products. The 2025 Repurchase Program authorizes the repurchase of up to $100,000,000 of common stock, with timing and amount contingent on capital resources, market conditions, and other factors.